National· August 17, 2026 at 05:02 p.m.
Health Canada Approves New Drug for Breast Cancer Patients' Menopause Symptoms
Key takeaways
- Health Canada has approved Elinzanetant (Lynkuet) for treating hot flashes and night sweats in breast cancer patients
- The drug's effectiveness was demonstrated in reducing these symptoms
- The approval aims to improve the quality of life for breast cancer patients
Health Canada has approved Elinzanetant, a drug marketed as Lynkuet, to treat hot flashes and night sweats in breast cancer patients who have entered menopause due to estrogen-suppressing treatment. The approval comes after the drug demonstrated effectiveness in reducing these symptoms.
